ALLMedicine™ Alopecia Center
Research & Reviews 4,309 results
https://doi.org/10.1007/s12032-023-01954-6
Medical Oncology (Northwood, London, England); Brianna , Lee SH
Feb 4th, 2023 - Chemotherapy is one of the widely used anticancer treatments that involves the use of powerful cytotoxic drugs to stop tumor growth by targeting rapidly dividing cells through various mechanisms, which will be elucidated in this review. Introduced...
https://doi.org/10.1097/PRS.0000000000010076
Plastic and Reconstructive Surgery; Papakonstantinou M, Siotos C et. al.
Feb 3rd, 2023 - Androgenic alopecia (AGA) is a common condition associated with hair loss both in men and women (female pattern hair loss, FPHL), causing considerable psychological distress. Ongoing research focuses on novel safe, cost-effective and efficient tre...
https://doi.org/10.1097/PRS.0000000000010000
Plastic and Reconstructive Surgery; Qu Q, He Y et. al.
Feb 3rd, 2023 - Studies have identified platelet-rich plasma (PRP) as a novel adjuvant therapy in AGA. However, the efficacy of PRP still needs to be improved. To assess the efficacy of PRP plus basic fibroblast growth factor (PRPF) for the treatment of AGA. This...
https://doi.org/10.1136/bcr-2022-254006
BMJ Case Reports; Engel ER, Ham JA
Feb 3rd, 2023 - We report a case of a woman in her 30s who struggled with a life-long history of trichotillomania (TTM; hair-pulling disorder), which was unsuccessfully treated with behavioural therapy and selective serotonin reuptake inhibitors. In addition to T...
https://doi.org/10.1111/pde.15266
Pediatric Dermatology; Lee WQ, Leong KF
Feb 3rd, 2023 - Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) is characterized by failure to thrive, severe chronic diarrhea, neonatal type 1 diabetes or thyroiditis, and eczematous dermatitis. We report a patient with infantile onset IPE...
Guidelines 3 results
https://doi.org/10.1111/1346-8138.14470
The Journal of Dermatology; Manabe M, Tsuboi R et. al.
Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...
https://doi.org/10.1111/jdv.12034
Journal of the European Academy of Dermatology and Venere... Lee WS, Lee HJ et. al.
Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...
https://doi.org/10.1111/j.1365-2133.2012.10955.x
The British Journal of Dermatology; Messenger AG, McKillop J et. al.
Apr 25th, 2012 - British Association of Dermatologists' guidelines for the management of alopecia areata 2012.|2012|Messenger AG,McKillop J,Farrant P,McDonagh AJ,Sladden M,|diagnosis,etiology,therapy,methods,therapeutic use,methods,methods,methods,
Drugs 471 results see all →
Clinicaltrials.gov 461 results
https://clinicaltrials.gov/ct2/show/NCT03474718
Feb 2nd, 2023 - Androgenic alopecia, or male-pattern hair loss affects both men and women. This hair loss pattern is typically characterized by thinning at the crown of scalp and/or M-shaped hair line in males or diffuse thinning throughout in females. Platelet-r...
https://clinicaltrials.gov/ct2/show/NCT05416333
Feb 2nd, 2023 - The management of Central Centrifugal Cicatricial Alopecia (CCCA) is challenging due to limited current treatments and a lack of randomized controlled trials. Management focuses on behavioral and styling modifications, in addition to symptomatic r...
https://clinicaltrials.gov/ct2/show/NCT05416320
Feb 2nd, 2023 - Calcipotriol, a vitamin D analog, has been topically used to treat alopecia areata, a form of non-scarring autoimmune alopecia in several studies. It is possible that Vitamin D plays a role in sustaining the hair follicle's immune privilege throug...
https://clinicaltrials.gov/ct2/show/NCT03898479
Feb 1st, 2023 - The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
https://clinicaltrials.gov/ct2/show/NCT04784533
Feb 1st, 2023 - This is a two part, double-blind, randomized, multicenter study to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.
News 1,253 results
https://www.medpagetoday.com/dermatology/generaldermatology/102901
Jan 31st, 2023 - Patients with alopecia areata (AA) had rates of anxiety and depression two to three times higher than the general population, and more than a third had suggestive symptoms, according to a meta-analysis of published data. The results showed a 9% pr...
https://www.mdedge.com/dermatology/article/260428/nonmelanoma-skin-cancer/epidermal-growth-factor-receptor-inhibitor
William Lewis, MD, Amy Forrestel, MD et. al.
Dec 30th, 2022 - Epidermal growth factor receptor (EGFR) inhibitors cause numerous cutaneous adverse events (AEs), including papulopustular eruptions, paronychia, acral fissures, xerosis, alopecia, and trichomegaly. 1 Symmetrical drug-related intertriginous and fle.
https://www.mdedge.com/dermatology/article/260423/hair-nails/alopecia-areata-skin-color-patients-new-considerations-sparked
Ivie Obeime, DO, Jorge Larrondo, MD et. al.
Dec 30th, 2022 - With the introduction of the first US Food and Drug Administration (FDA)–approved medication for alopecia areata (AA)—the Janus kinase (JAK) inhibitor, baricitinib—there is an important focus on this disease in the literature and for practicing de.
https://www.mdedge.com/dermatology/article/260391/hair-nails/study-evaluates-features-alopecia-areata-hispanic/latinx
Doug Brunk
Dec 29th, 2022 - Among Hispanic/Latinx patients with alopecia areata, the mean age at diagnosis was 33 years, 24% had concomitant atopy, and 18% had one or more coexisting autoimmune conditions, most commonly rheumatoid arthritis. Those are among key findings from.
https://www.medpagetoday.com/urology/urology/102369
Dec 22nd, 2022 - Men taking 5α-reductase inhibitors (5-ARIs), commonly used for androgenic alopecia and benign prostatic hyperplasia (BPH), should be aware of possible adverse psychological effects, researchers warned. In a register-based cohort study of over 2.2 ...